0001502152 2022-10-01 2023-03-31 0001502152 2023-05-25 0001502152 2023-03-31 0001502152 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesDPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesFPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2023-03-31 0001502152 us-gaap:SeriesGPreferredStockMember 2022-09-30 0001502152 2021-10-01 2022-09-30 0001502152 2023-01-01 2023-03-31 0001502152 2022-01-01 2022-03-31 0001502152 2021-10-01 2022-03-31 0001502152 us-gaap:CommonStockMember 2021-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001502152 gstc:StockPayableMember 2021-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-09-30 0001502152 2021-09-30 0001502152 us-gaap:CommonStockMember 2021-12-31 0001502152 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001502152 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001502152 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001502152 us-gaap:SeriesFPreferredStockMember 2021-12-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001502152 gstc:StockPayableMember 2021-12-31 0001502152 us-gaap:RetainedEarningsMember 2021-12-31 0001502152 2021-12-31 0001502152 us-gaap:CommonStockMember 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001502152 gstc:StockPayableMember 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-09-30 0001502152 us-gaap:CommonStockMember 2022-12-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001502152 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001502152 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001502152 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001502152 gstc:StockPayableMember 2022-12-31 0001502152 us-gaap:RetainedEarningsMember 2022-12-31 0001502152 2022-12-31 0001502152 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001502152 us-gaap:SeriesAPreferredStockMember 2021-10-01 2021-12-31 0001502152 us-gaap:SeriesDPreferredStockMember 2021-10-01 2021-12-31 0001502152 us-gaap:SeriesEPreferredStockMember 2021-10-01 2021-12-31 0001502152 us-gaap:SeriesFPreferredStockMember 2021-10-01 2021-12-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001502152 gstc:StockPayableMember 2021-10-01 2021-12-31 0001502152 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001502152 2021-10-01 2021-12-31 0001502152 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001502152 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-03-31 0001502152 us-gaap:SeriesEPreferredStockMember 2022-01-01 2022-03-31 0001502152 us-gaap:SeriesFPreferredStockMember 2022-01-01 2022-03-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001502152 gstc:StockPayableMember 2022-01-01 2022-03-31 0001502152 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001502152 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-10-01 2022-12-31 0001502152 us-gaap:SeriesDPreferredStockMember 2022-10-01 2022-12-31 0001502152 us-gaap:SeriesEPreferredStockMember 2022-10-01 2022-12-31 0001502152 us-gaap:SeriesFPreferredStockMember 2022-10-01 2022-12-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001502152 gstc:StockPayableMember 2022-10-01 2022-12-31 0001502152 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001502152 2022-10-01 2022-12-31 0001502152 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001502152 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001502152 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-03-31 0001502152 us-gaap:SeriesEPreferredStockMember 2023-01-01 2023-03-31 0001502152 us-gaap:SeriesFPreferredStockMember 2023-01-01 2023-03-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001502152 gstc:StockPayableMember 2023-01-01 2023-03-31 0001502152 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001502152 us-gaap:CommonStockMember 2022-03-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001502152 us-gaap:SeriesDPreferredStockMember 2022-03-31 0001502152 us-gaap:SeriesEPreferredStockMember 2022-03-31 0001502152 us-gaap:SeriesFPreferredStockMember 2022-03-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001502152 gstc:StockPayableMember 2022-03-31 0001502152 us-gaap:RetainedEarningsMember 2022-03-31 0001502152 2022-03-31 0001502152 us-gaap:CommonStockMember 2023-03-31 0001502152 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001502152 gstc:StockPayableMember 2023-03-31 0001502152 us-gaap:RetainedEarningsMember 2023-03-31 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-10-01 2023-03-31 0001502152 gstc:ConvertibleNoteDateApril132017Member 2023-03-31 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-09-30 0001502152 us-gaap:ConvertibleDebtMember 2022-10-01 2023-03-31 0001502152 us-gaap:ConvertibleDebtMember 2023-03-31 0001502152 gstc:AdvanceMember 2023-03-31 0001502152 gstc:AdvanceMember 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2023-03-31 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2022-02-01 2022-02-28 0001502152 srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001502152 gstc:MrKatzaroffMember 2022-10-01 2023-03-31 0001502152 us-gaap:SeriesAPreferredStockMember 2022-10-01 2023-03-31 0001502152 us-gaap:SeriesBPreferredStockMember 2022-10-01 2023-03-31 0001502152 us-gaap:SeriesCPreferredStockMember 2017-09-12 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-03 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-02 2015-08-03 0001502152 srt:DirectorMember us-gaap:SeriesEPreferredStockMember 2023-03-31 0001502152 srt:DirectorMember us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:SeriesFPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:CashMember 2022-09-30 0001502152 2022-01-01 2022-09-30 0001502152 us-gaap:CashMember 2023-03-31 0001502152 us-gaap:WarrantMember 2022-10-01 2023-03-31 0001502152 us-gaap:CashMember 2023-02-28 0001502152 us-gaap:CommonStockMember 2023-02-01 2023-02-28 0001502152 us-gaap:CommonStockMember 2023-02-28 0001502152 us-gaap:WarrantMember 2023-03-31 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-09 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2022-10-01 2023-03-31 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2022-10-01 2023-03-31 0001502152 us-gaap:PatentsMember gstc:FabrizioDeSilvestriMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 us-gaap:PatentsMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 2021-08-22 2021-08-23 0001502152 2022-02-26 2022-02-28 0001502152 us-gaap:SubsequentEventMember gstc:LicenseAgreementMember 2023-04-25 0001502152 us-gaap:SubsequentEventMember gstc:LicenseAgreementMember 2023-04-23 2023-04-25 0001502152 us-gaap:SubsequentEventMember gstc:SecuritiesPurchaseAgreementMember 2023-05-08 2023-05-10 0001502152 us-gaap:SubsequentEventMember gstc:SecuritiesPurchaseAgreementMember 2023-05-10 iso4217:USD shares iso4217:USD shares pure 0001502152 false 2023 Q2 --09-30

Unlimited

P2Y5M12D

P1Y4M9D

2024-05-10

10-Q true 2023-03-31 false 333-170315 GlobeStar Therapeutics Corporation WY 27-3480481 719 Jadwin Avenue Richland WA 99352 206 451-1970 Yes Yes Non-accelerated Filer false true false false Common GSTC 787688270

176

6365

3550

176

9915

176

9915

450135

380735

467981 379126 13100 12400 59650 59650

20000

13097 12581 76003 126294

223977

226270

1290846

1204475

1290846

1204475

0.001

780427183

722326669

780425

722325

20000000

0.001

509988

510

0.001

1000000

1000

0.001

128991

129

16723188

16581252

10530304 1515152 25000 5000

-18820922

-18504776

-1290670

-1194560

176

9915

142059

662310

297300

828604

142059

662310

297300

828604

-142059

-662310

-297300

-828604

-146460

8178

26248

18846

46335

-8178

-26248

-18846

-192795

-150237

-688558

-316146

-1021399

-0.00 -0.00 -0.00 -0.00 773432215 600796122 764419403 586965040

561495726

561494

509988

510

1000000

1000

386975

387

15228254

499500

-17016966

-725821

12899100 12899 -128991 -129 -12770 19980000

19980

479520

-499500

6000000 6000 155460 161460

-332841

600374826

600373

509988

510

1000000

1000

257984

258

15850464

-17349807

-897202

5416667 5417 20583 26000

322266

154095 154095

-688558

605791493

605790

509988

510

1000000

1000

257984

258

16347408

-18038365

-1083399

722326669

722325

509988

510

1000000

1000

128991

129

16581252

5000

-18504776

-1194560

5000

48033947 48034 52066 100100 17803 17803

-165909

770360616

770359

509988

510

1000000

1000

128991

129

16651121

10000

-18670685

-1237566

15000

2000000 2000 18000 20000 8066567 8066 36264 44330 17803 17803

-150237

780427183

780425

509988

510

1000000

1000

128991

129

16723188

25000

-18820922

-1290670

-316146

-1021399

322266

35606 154095

15584

35417

-146460

-3550

76400

17981

88855

93878

3262

10918

-92889

-240384

73000 235000

700

13000

86700

235000

-6189

-5384

6365

5960

176

576

12889 144430 25000 499500 20000 15000 7000

Note 1. General Organization and Business GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation. The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 6.

Note 2. Going Concern and Summary of Significant Accounting Policies The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended March 31, 2023, the Company had a net loss of $316,146 and cash flow used in operating activities of $92,889. As of March 31, 2023, the Company had negative working capital of $1,290,670. Management does not anticipate having positive cash flow from operations in the near future. The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Management has plans to address the Company’s financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern. In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations. Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2022 which are included on our Form 10-K filed on January 9, 2023. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the three and six months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2023. Consolidated Financial Statements The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation. Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

-316146

-92889

1290670

Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2022 which are included on our Form 10-K filed on January 9, 2023. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the three and six months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2023.

Consolidated Financial Statements The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Note 3. Convertible Notes Payable Convertible notes payable consisted of the following at March 31, 2023 and September 30, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, 2023</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zHa4d9cc93j9" title="Conversion price">0.01 per share.</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zKZepX5qnNw8" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">—</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zS2y1D6YdQ56" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230331_zoKQyxHjoYbi" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">—</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98F_eus-gaap--ConvertibleDebt_iI_c20220930_zmrjCyth99g1" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">20,000</td> <td> </td></tr> </table> All principal along with accrued interest is payable on the maturity date. <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20221001__20230331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHDUptHChsm5" title="Beneficial conversion discount on convertible note payable">The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company. As of March 31, 2023 and September 30, 2022, accrued interest on convertible notes payable was $222,287. Conversions to Common Stock During the six months ended March 31, 2023, the holders of the convertible notes payable elected to convert principal of $20,000 into 2,000,000 shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized. Advances As of March 31, 2023 and September 30, 2022, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.

Convertible notes payable consisted of the following at March 31, 2023 and September 30, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, 2023</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zHa4d9cc93j9" title="Conversion price">0.01 per share.</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zKZepX5qnNw8" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">—</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zS2y1D6YdQ56" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230331_zoKQyxHjoYbi" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">—</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98F_eus-gaap--ConvertibleDebt_iI_c20220930_zmrjCyth99g1" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">20,000</td> <td> </td></tr> </table>

2017-04-13

20000

0.03

0.01

20000

The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company.

222287

20000

2000000

59650

Note 4. Related Party Transactions As of March 31, 2023 and September 30, 2022, the Company owed $467,981 and $379,126 to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, the Company received short term, unsecured, non-interest bearing advances from the Company’s CEO totaling $700. As of March 31, 2023, the Company owed $13,100 on these related party advances. In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $<span id="xdx_90D_eus-gaap--ProfessionalFees_pp0p0_c20220201__20220228__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zcZjzuSykZ8c" title="Annual fees">180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior three years. The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $0.009 per share, an exercise term of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20221001__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcw4PyHVkqG3" title="Excercise term">five years. The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $284,840. During the six months ended March 31, 2023 and 2022, the Company recognized $35,606 and $154,095 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At March 31, 2023, the Company had $62,308 of unrecognized expense related to options. Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of March 31, 2023, no amounts have been earned or paid. Mr. Katzaroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of March 31, 2023, no amounts have been earned or paid.

467981 379126

700

13100

180000

P3Y

35000000

0.009

P5Y

The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $284,840. During the six months ended March 31, 2023 and 2022, the Company recognized $35,606 and $154,095 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At March 31, 2023, the Company had $62,308 of unrecognized expense related to options. Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of March 31, 2023, no amounts have been earned or paid.

Note 5. Stockholders’ Deficit Preferred Stock Series A Preferred Stock – Our board of directors has designated up to <span id="xdx_90A_ecustom--PreferredStockSharesDesignate_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsIKb6mLKvF" title="Preferred stock, shares designated">6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmg6ZRJenVW4" title="Preferred stock liquidation preference">2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of <span id="xdx_900_eus-gaap--PreferredStockDividendsShares_pid_uShares_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVp3mTdtoe1g" title="Preferred stock dividends">6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an <span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr4iEWtOlxG2" title="Preferred stock dividend rate">8% per annum dividend, payable in additional shares of Series A Preferred Stock. At March 31, 2023 and September 30, 2022, there were <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5VkhtTDf6uc" title="Preferred Stock, Shares Outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5rcwrUckCf2" title="Preferred Stock, Shares Outstanding">no shares of our Series A Preferred Stock outstanding, respectively. Series B Preferred Stock – Our board of directors has designated up to <span id="xdx_90E_ecustom--PreferredStockSharesDesignate_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfUrqe0yziAc" title="Preferred stock, shares designated">1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0146BocxeU9" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQdlTYelwcc3" title="Preferred stock dividend rate">8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At March 31, 2023 and September 30, 2022, there were <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqczqAnqpWsi" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHi5SClEEzK5" title="Preferred stock, shares outstanding">no shares of our Series B Preferred Stock outstanding. Series C Preferred Stock – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $<span id="xdx_902_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJSZ0yN52Gcg" title="Preferred stock redemption price per share">0.50 per share. The Series C Preferred Stock has been canceled, and there are <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwErMhzFXmA2" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOr4RxstUqo9" title="Preferred stock, shares outstanding">no shares of Series C Preferred Stock outstanding as of March 31, 2023 and September 30, 2022. Series D Preferred Stock – On September 21, 2017, our board of directors designated up to <span id="xdx_905_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zrKXF676UQA7" title="Preferred stock, shares designated">539,988 shares of Series D Preferred Stock with a liquidation value of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zAd9QDNtEgi1" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series D Preferred Stock have no voting rights. <span id="xdx_90F_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zdiY2hi8edll" title="Preferred stock, conversion basis">The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. At March 31, 2023 and September 30, 2022, there were 509,988 shares of Series D Preferred Stock outstanding. Series E Preferred Stock – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company. At March 31, 2023 and September 30, 2022, there were <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZAvkzV1dfGj" title="Preferred stock authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2omiGSdu2K" title="Preferred stock authorized">1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes. Series F Preferred Stock – On September 21, 2017, our board of directors designated up to <span id="xdx_905_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z6uPkcaPeFyl" title="Preferred stock, shares designated">501,975 shares of Series F Preferred Stock with a liquidation value of $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zo6pVBxiY742" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series F Preferred Stock have no voting rights. <span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zx2TLOBtCyGg" title="Preferred stock, conversion basis">The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, <span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zPdaUYBivZGd" title="Convertible preferred stock shares">257,984 shares of Series F Preferred Stock was converted into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zTS7uAMxAlqa" title="Conversion of shares converted">25,798,400 shares of common stock. At March 31, 2023 and September 30, 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding. Common stock issued for stock payable In September 2022, the Company received $5,000 of cash as a subscription for 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. In December 2022, the Company received $5,000 of cash as a subscription for an additional <span id="xdx_900_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_uShares_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdjGfC5GRkB3" title="Common stock subscribed but unissued">1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. The warrants had a fair value of $4,067 based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 176.37%; 2) risk free rate of 4.74%; 3) dividend yield of 0% and 4) expected term of 1 year. In February 2023, the Company received $8,000 of cash and $7,000 of expenses paid on the Company’s behalf as a subscription for <span id="xdx_904_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_uShares_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyoCdKrTvXtl" title="Common Stock, Shares Subscribed but Unissued">7,500,000 shares of common stock. The common shares were not yet issued as of March 31, 2023. Common Stock Warrants The following table summarizes the stock warrant activity for the six months ended March 31, 2023: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2022</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20221001__20230331_zKidm1YIgQbf" style="width: 13%; text-align: right" title="Warrants outstanding, begnning">71,385,152</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230331_zNMRcmWpUQJ4" style="width: 13%; text-align: right" title="Warrants outstanding, begnning">0.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20221001__20230331_zadueJIskAJ9" style="text-align: right" title="Granted">1,515,152</td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230331_zL9tZmBVoiGc" style="text-align: right" title="Granted">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding, March 31, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20221001__20230331_zCHCtKe0CcNh" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">72,900,304</td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230331_zLl111FGNyO8" style="text-align: right" title="Warrants outstanding, ending">0.02</td> <td> </td></tr> </table> As of March 31, 2023, the outstanding warrants had an expected remaining life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqvcOTM6W9Al" title="::XDX::P2Y5M12D">2.45 years and have <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_do_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8HtKy88StR3">no aggregate intrinsic value. Common Stock Options The Company recognized $35,606 of expense related to the fair value of options vesting during the six months ended March 31, 2023. At March 31, 2023, the Company had $62,308 of unrecognized expenses related to options. The following table summarizes the stock option activity for the six months ended March 31, 2023: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Options</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2022</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20221001__20230331_zptyUmpOFHeb" style="width: 13%; text-align: right" title="Option outstanding, beginning">105,000,000</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230331_zUFIEwZmLGHd" style="width: 13%; text-align: right" title="Option outstanding, per shares, beginning">0.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding, March 31, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20221001__20230331_zDFaSy7mrp0j" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">105,000,000</td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230331_zekpal2v4ncg" style="text-align: right" title="Option outstanding, per shares, ending">0.02</td> <td> </td></tr> </table> As of March 31, 2023, all outstanding options had an expected remaining life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20221001__20230331_zhuTUwWn3oSa" title="Expected remaining life::XDX::P1Y4M9D">1.36 years and have <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_do_c20230331_zIcLRgMlvCLd" title="Aggregate intrinsic value">no aggregate intrinsic value.

6000000

2.00

5000000

6000000

0.08

1000000

1.00

0.08

1200000

0.50

539988

1.00

The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.

509988

1000000

The Series E Preferred stock retained 2/3 of the voting rights in the Company

1000000

501975

1.00

The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock

386975

257984

25798400

128991

5000

1515152

0.01

5000

1515152

0.01

The warrants had a fair value of $4,067 based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 176.37%; 2) risk free rate of 4.74%; 3) dividend yield of 0% and 4) expected term of 1 year.

8000

7000

7500000

The following table summarizes the stock warrant activity for the six months ended March 31, 2023: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2022</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20221001__20230331_zKidm1YIgQbf" style="width: 13%; text-align: right" title="Warrants outstanding, begnning">71,385,152</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230331_zNMRcmWpUQJ4" style="width: 13%; text-align: right" title="Warrants outstanding, begnning">0.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20221001__20230331_zadueJIskAJ9" style="text-align: right" title="Granted">1,515,152</td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230331_zL9tZmBVoiGc" style="text-align: right" title="Granted">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding, March 31, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20221001__20230331_zCHCtKe0CcNh" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">72,900,304</td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230331_zLl111FGNyO8" style="text-align: right" title="Warrants outstanding, ending">0.02</td> <td> </td></tr> </table> 71385152 0.02 1515152 0.01 72900304 0.02

35606

62308

The following table summarizes the stock option activity for the six months ended March 31, 2023: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Options</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2022</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20221001__20230331_zptyUmpOFHeb" style="width: 13%; text-align: right" title="Option outstanding, beginning">105,000,000</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230331_zUFIEwZmLGHd" style="width: 13%; text-align: right" title="Option outstanding, per shares, beginning">0.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding, March 31, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20221001__20230331_zDFaSy7mrp0j" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">105,000,000</td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230331_zekpal2v4ncg" style="text-align: right" title="Option outstanding, per shares, ending">0.02</td> <td> </td></tr> </table>

105000000

0.02

105000000

0.02

Note 6. Series G Preferred Stock On August 11, 2021, our board of directors designated up to <span id="xdx_90B_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zeDIP7zEsW32" title="Preferred stock, shares designated">1,000,000 shares of Series G Preferred Stock with a liquidation value of $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zSXe3IM8blW1" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. <span id="xdx_902_eus-gaap--PreferredStockConversionBasis_c20210809__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zwTJLMn8XgBe" title="Preferred stock, conversion basis">The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement. Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into. During the six months ended March 31, 2023, the Company sold an aggregate of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zezZhH4kwDSa" title="Number of share sold">89,100 shares of Series G Preferred Stock for net cash proceeds of $73,000. The Company recorded a debt discount of $16,100 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $89,100. The Company amortized $15,584 of discount related to Series G Preferred Stock for the six months ended March 31, 2023. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $3,262 of interest on the Series G Preferred Stock and had an accrued interest balance of $1,690 and $3,983 as of March 31, 2023 and September 30, 2022, respectively. During the six months ended March 31, 2023, the holder of the Series G converted <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zwzuU8bv3lab" title="Conversion of stock shares converted">138,875 shares of Series G and $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockDividend_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztMmvRmixxJ1" title="Dividend value">5,555 of dividends into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcznbZqGg7y1" title="Conversion of stock shares converted">56,100,514 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized. As of March 31, 2023 and September 30, 2022, <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_znHl86D4Kbxa" title="Preferred stock, shares outstanding">89,100 and <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zyeDzeyEvl2i" title="Preferred stock, shares outstanding">138,875 shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $76,003 and $126,294, respectively, net of unamortized discount of $13,097 and $12,581, respectively. 1000000

1.00

The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default.

89100

73000

16100

89100

15584

3262

1690

3983

138875

5555

56100514

89100

138875

76003

126294

13097

12581

Note 7. License Agreement Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FabrizioDeSilvestriMember_zkvlNvKFkxfa" title="Rights to issued">10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of <span id="xdx_906_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIUpJYZSuVJ4" title="Royalty of net sales">7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: center">●</td> <td style="width: 7in; text-align: justify">Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify">29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify">29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify">Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify">$40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.</td></tr> </table> The Company paid no royalties and accrued $23,852 of royalties and late fees during the six months ended March 31, 2023. The Company owes $50,102 of royalties and late fees under this agreement as of March 31, 2023 and $26,250 as of September 30, 2022. The Company is currently in default of this agreement.

10610592

0.071 Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021. 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021. 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met. $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

23852

50102

26250

Note 8. Commitments In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. Concurrently, the Consultant entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares was to be completed by June 30, 2022 but has not yet occurred. The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock. The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. As of March 31, 2023 and September 30, 2022, the Company owed the consultant $162,500 and $100,000, respectively, included in accounts payable and accrued liabilities.

6000000

25000

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.

162500

100000

Note 9. Subsequent Events On April 25, 2023, the Company issued <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230425__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBzeH4GRtB19" title="Common stock, shares, issued">7,261,087 shares of common stock to 7 to Stand to settle the outstanding royalty balance of $50,102 under the License Agreement. On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “May 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the May 2023 Securities Purchase Agreement, the Company agreed to issue a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230508__20230510__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7u8NWGChxjk" title="Aggregate principal amount">21,300. Effective May 10, 2023, the Company issued the May 2023 Note to 1800 Diagonal consistent with the terms of the May 2023 Securities Purchase Agreement. The May 2023 Note bears interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230510__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zm9ynFhgFZWi" title="Interest rate">12%, with an Original Issue Discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230510__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z8mqnuc6PEej" title="Discount issued">1,050 and matures on <span id="xdx_909_eus-gaap--LongTermDebtMaturityDate_iI_ddxL_c20230510__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLiftBmBMzri" title="Maturity date::XDX::2024-05-10">May 10, 2024. Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible into shares of the Company’s common stock as set forth therein.

7261087

50102

21300

0.12

1050